May 14, 2025FinancialNotice concerning differences in non-consolidated financial results between FY2023 and FY2024 (PDF 108.74 KB)
May 14, 2025CorporateTerumo and WuXi Biologics Enter into Agreement on a Drug Product Plant in Leverkusen, GermanyExpanding production capacity and global responsiveness of Terumo’s CDMO business
Investors Japanese Financial Results for the Fiscal Year Ended 3/2025 May 14, 2025 IR Library Audio Webcast Stock Quote Prime Market of TSE: Last Trade JPY Change JPY (%) Volume View Chart Top Management Message Hikaru Samejima Chief Executive Officer GS26: 5-Year Growth strategy 2022 - 2026 IR Library IR materials and various reports Terumo Report Integrated Report 2024 Sustainability Sustainability at the Terumo Group From Devices to Solutions Vision for the Next 10 Years Shareholders & Stock Information on shareholders meeting and stock What's New May 16, 2025 Q&A regarding Financial Results for FYE 3/2025 May 15, 2025 Audio webcast regarding Financial Results for FYE 3/2025 May 14, 2025 Presentation regarding Financial Results for FYE 3/2025 May 14, 2025 Notice concerning differences in non-consolidated financial results between FY2023 and FY2024 (PDF 108.74 KB) April 01, 2025 Terumo announces changes to the names of some businesses within the Cardiac and Vascular Company (PDF 77.82 KB) Disclosure segments of Blood and Cell Technologies Company to also be revised View all Business Overview Introduction to the businesses operated by the Terumo Group /business Technology Introduction to Terumo's research and development activities and production system /technology
May 14, 2025 Notice concerning differences in non-consolidated financial results between FY2023 and FY2024 (PDF 108.74 KB)
April 01, 2025 Terumo announces changes to the names of some businesses within the Cardiac and Vascular Company (PDF 77.82 KB) Disclosure segments of Blood and Cell Technologies Company to also be revised
